Effect Of A Treatment Optimization Program To Improve Satisfaction With Viagra
Phase 4
Completed
- Conditions
- Impotence
- Registration Number
- NCT00159848
- Lead Sponsor
- Pfizer
- Brief Summary
This study will demonstrate if a treatment optimization program has an impact on the satisfaction with Viagra treatment in men with erectile dysfunction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 8000
Inclusion Criteria
- Male subjects above age of majority for whom sildenafil is prescribed for the first time within the usual practice of medicine
Exclusion Criteria
- Male subjects who have used any ED medical treatments over the last month, with the exception of testosterone and/or herbal therapies
- Subjects who do not have the possibility of viewing the video either through a computer, VCR or a DVD
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Assess the impact of a sildenafil educational program versus usual care on subjects' satisfaction regarding their management of ED with sildenafil as assessed through the validated EDITS questionnnaire after 3 months of treatment
- Secondary Outcome Measures
Name Time Method Describe the relationship between the administration of an educational program and the effectiveness of sildenafil; Evaluate the educational program as a tool to help physicians in their management of ED; Estimate the intracluster correlation coefficient
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of sildenafil improve erectile dysfunction satisfaction in NCT00159848?
How does the educational program in NCT00159848 compare to standard-of-care for ED management?
Are there specific biomarkers that predict patient response to sildenafil optimization programs?
What adverse events are associated with long-term sildenafil use in ED treatment?
How do phosphodiesterase inhibitors like sildenafil compare to other ED therapies in clinical practice?